Skip to main content

Isis to Receive $1.1M from Alnylam

Premium

Isis Pharmaceuticals this week said that it stands to receive a $1.1 million payment tied to Alnylam Pharmaceuticals' strategic alliance with Genyzme.

This week, Alnylam announced that it has partnered with Genzyme to develop and commercialize RNAi-based treatments for TTR-mediated amyloidosis. Genzyme will have product rights in Asia (see related story, this issue).

Isis said that the money, to be paid by Alnylam, reflects its share of the upfront fees Alnylam is receiving from Genzyme. Isis is entitled to a portion of payments Alnylam receives on licenses to products enabled by Isis intellectual property pursuant to their ongoing IP cross-licensing arrangement.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.